

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1 – 5. Cancelled.

6 (Currently Amended). A therapeutic vaccine against tuberculosis comprising one or more polypeptides or fragments thereof and a pharmaceutically acceptable polymeric carrier, a pharmaceutically acceptable vehicle or a pharmaceutically acceptable adjuvant, which polypeptides are upregulated or expressed during the latent stage of the mycobacteria infection.

7 (Previously Presented). A therapeutic vaccine according to claim 6 where the polypeptides upregulated or expressed during the latent stage of the mycobacteria infection, which stage is characterized by low-oxygen tension in the microenvironment of the mycobacteria, comprises one or more amino acid sequences selected from

(a) SEQ ID NO 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 and 45

(b) an immunogenic portion, e.g. a T-cell epitope, of any one of the sequences in (a); and /or

(c) an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic.

8 (Original). A therapeutic vaccine according to claim 7, where the immunogenic portions are selected from the group consisting of SEQ ID NO 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 and 45.

9 (Previously Presented). A therapeutic vaccine against tuberculosis comprising one or more polypeptides or fragments thereof, which polypeptides are upregulated or expressed during the latent stage of the mycobacteria infection, wherein at least one of the one or more polypeptides or fragments thereof, is fused to at least one fusion partner which is an antigen expressed by bacteria within the mycobacteria family.

10 (Previously Presented). A therapeutic vaccine according to claim 9 where the fusion partner is selected from the group consisting of ESAT-6, ESAT-6-Ag85B, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59), MPB59, Ag85C, 19kDa lipoprotein, MPT32.

Claim 11. Cancelled.

12 (Previously Presented). A multiphase vaccine comprising antigen components with therapeutic activity against tuberculosis comprising one or more polypeptides or fragments thereof, which polypeptides are upregulated or expressed during the latent stage of the mycobacteria infection, combined with antigen components with prophylactic activity.

13 (Previously Presented). A multiphase vaccine according to claim 12 where the antigen components with prophylactic activity are selected from the group consisting of ESAT-6, ESAT-6-Ag85B, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59), MPB59, Ag85C, 19kDa lipoprotein or MPT32.

Claims 14 and 15. Cancelled.

16 (Previously Presented). A therapeutic vaccine against tuberculosis comprising one or more polypeptides or fragments thereof and a pharmaceutically acceptable carrier, vehicle or adjuvant, which polypeptides are upregulated or expressed during the latent stage of the mycobacteria infection, where the polypeptides or fragments are recombinant or synthetic and are delivered in a delivery system such as an adjuvant.

17 (Previously Presented). A therapeutic vaccine against tuberculosis comprising one or more polypeptides or fragments thereof and a pharmaceutically acceptable carrier, vehicle or adjuvant, which polypeptides are upregulated or expressed during the latent stage of the mycobacteria infection, in which the polypeptide or fragment is lipidated so as to allow a self-adjuvanting effect of the polypeptide.

Claims 18 – 22. Cancelled.

23 (New). The therapeutic vaccine according to claim 6, wherein the polymeric carrier is bound to the one or more polypeptide(s) or fragments thereof.

24 (New). The therapeutic vaccine according to claim 23, wherein the polymeric carrier and the one or more polypeptide(s) are bound by non-covalent interactions.

25 (New). The therapeutic vaccine according to claim 24, wherein the polymeric carrier is a polystyrene.

26 (New). The therapeutic vaccine according to claim 6, wherein the polymeric carrier and the one or more polypeptide(s) or fragments thereof are bound by covalent interactions.

27 (New). The therapeutic vaccine according to claim 26, wherein the polymeric carrier is selected from the group consisting of a polysaccharide or a polypeptide.